Stock PCIB PCI BIOTECH HOLDING ASA
Add to a list
To use this feature you must be a member
Log inSign up

Financials PCI Biotech Holding ASA

Equities

PCIB

NO0010405640

Biotechnology & Medical Research

Market Closed - Oslo Bors
Other stock markets
 10:45:00 2024-04-26 am EDT 		5-day change 1st Jan Change
1.618 NOK -0.12% Intraday chart for PCI Biotech Holding ASA -4.82% -22.77%
Feb. 14 PCI Biotech Holding ASA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Pci Biotech Initiates Field Testing of Its Proprietary Technology for Gene Therapy Manufacturing CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 1,052 977.4 2,858 1,041 519.2 76.52
Enterprise Value (EV) 1 1,001 628.1 2,598 854.1 405 20.69
P/E ratio -23.9 x -21 x -32.2 x -14.4 x -5.87 x -1.39 x
Yield - - - - - -
Capitalization / Revenue 103 x 102 x 304 x 141 x 82.8 x 16.1 x
EV / Revenue 97.7 x 65.5 x 277 x 116 x 64.6 x 4.36 x
EV / EBITDA -23.1 x -14.1 x -29.4 x -10.6 x -4.82 x -0.37 x
EV / FCF -72.3 x -26.8 x -49 x -17 x -11.1 x -0.46 x
FCF Yield -1.38% -3.73% -2.04% -5.88% -9.04% -217%
Price to Book 25.1 x 2.88 x 11.2 x 5.5 x 4.56 x 1.33 x
Nbr of stocks (in thousands) 24,987 37,165 37,266 37,326 37,326 37,326
Reference price 2 42.10 26.30 76.70 27.90 13.91 2.050
Announcement Date 3/19/18 4/9/19 4/22/20 4/21/21 4/28/22 4/28/23
1NOK in Million2NOK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 10.25 9.585 9.392 7.368 6.273 4.75
EBITDA 1 -43.42 -44.51 -88.45 -80.52 -84.11 -56.43
EBIT 1 -43.43 -44.52 -88.8 -82.12 -86.03 -56.45
Operating Margin -423.72% -464.47% -945.52% -1,114.55% -1,371.42% -1,188.36%
Earnings before Tax (EBT) 1 -42.84 -34.78 -88.75 -72.24 -88.39 -55.1
Net income 1 -42.84 -34.78 -88.75 -72.24 -88.39 -55.1
Net margin -417.96% -362.86% -944.91% -980.44% -1,409.07% -1,159.89%
EPS 2 -1.760 -1.251 -2.384 -1.937 -2.368 -1.476
Free Cash Flow 1 -13.85 -23.4 -53.03 -50.26 -36.62 -44.95
FCF margin -135.16% -244.18% -564.59% -682.11% -583.72% -946.37%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/19/18 4/9/19 4/22/20 4/21/21 4/28/22 4/28/23
1NOK in Million2NOK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 50.8 349 260 187 114 55.8
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -13.9 -23.4 -53 -50.3 -36.6 -45
ROE (net income / shareholders' equity) -156% -18.2% -29.8% -32.5% -58.3% -64.4%
ROA (Net income/ Total Assets) -67.2% -13.4% -17.4% -20.9% -31.2% -35.4%
Assets 1 63.79 259.7 510.9 345.6 283.7 155.7
Book Value Per Share 2 1.670 9.150 6.840 5.070 3.050 1.540
Cash Flow per Share 2 2.030 9.400 7.010 5.040 3.110 1.520
Capex - - 5.41 3.92 0.34 -
Capex / Sales - - 57.55% 53.19% 5.44% -
Announcement Date 3/19/18 4/9/19 4/22/20 4/21/21 4/28/22 4/28/23
1NOK in Million2NOK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
PCI BIOTECH HOLDING ASA Stock PCI Biotech Holding ASA
-22.77% 5.47M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. PCIB Stock
  4. Financials PCI Biotech Holding ASA